US FDA approval of Sanofi/Regeneron Pharmaceuticals Inc's PD-1 inhibitor Libtayo (cemiplimab-rwlc) in a niche market for cutaneous squamous cell carcinoma (CSCC) paves the way for development across a range of other indications as well for the partners' immuno-oncology strategy more generally.
FDA approved Libtayo on Sept. 28 for locally advanced squamous cell carcinoma (CSCC) in patients who are not candidates fur...







